-“IMFINZI is first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer”, presented at WCLC plenary session:
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2019/rns1.html